Imaging biomarkers for evaluating tumor response: RECIST and beyond

doi:10.1186/s40364-021-00306-8

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 保健營養系(所) > 期刊論文 > Item 310902800/34396

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34396

標題:	Imaging biomarkers for evaluating tumor response: RECIST and beyond
作者:	Ko, Ching-Chung Yeh, Lee-Ren Kuo, Yu-Ting Chen, Jeon-Hor
貢獻者:	Chi Mei Med Ctr, Dept Med Imaging Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr I Shou Univ, E DA Hosp, Dept Radiol Kaohsiung Med Univ Hosp, Dept Med Imaging Univ Calif Irvine, Dept Radiol Sci, Tu & Yuan Ctr Funct Oncoimaging
關鍵字:	RECIST Imaging biomarker Tumor response
日期:	2021
上傳時間:	2023-11-11 11:49:31 (UTC+8)
出版者:	BMC
摘要:	Response Evaluation Criteria in Solid Tumors (RECIST) is the gold standard for assessment of treatment response in solid tumors. Morphologic change of tumor size evaluated by RECIST is often correlated with survival length and has been considered as a surrogate endpoint of therapeutic efficacy. However, the detection of morphologic change alone may not be sufficient for assessing response to new anti-cancer medication in all solid tumors. During the past fifteen years, several molecular-targeted therapies and immunotherapies have emerged in cancer treatment which work by disrupting signaling pathways and inhibited cell growth. Tumor necrosis or lack of tumor progression is associated with a good therapeutic response even in the absence of tumor shrinkage. Therefore, the use of unmodified RECIST criteria to estimate morphological changes of tumor alone may not be sufficient to estimate tumor response for these new anti-cancer drugs. Several studies have reported the low reliability of RECIST in evaluating treatment response in different tumors such as hepatocellular carcinoma, lung cancer, prostate cancer, brain glioma, bone metastasis, and lymphoma. There is an increased need for new medical imaging biomarkers, considering the changes in tumor viability, metabolic activity, and attenuation, which are related to early tumor response. Promising imaging techniques, beyond RECIST, include dynamic contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI), diffusion-weight imaging (DWI), magnetic resonance spectroscopy (MRS), and (18) F-fluorodeoxyglucose (FDG) positron emission tomography (PET). This review outlines the current RECIST with their limitations and the new emerging concepts of imaging biomarkers in oncology.
關聯:	BIOMARK RES, v.9, n.1
显示于类别:	[保健營養系(所) ] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	112	检视/开启
s40364-021-00306-8.pdf		4628Kb	Adobe PDF	78	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....